Current studies are focused on using genetic mouse models for pancreatic cancer in which both MALAT-1 and Sp transcription factors can be deleted (tissue-specific) or specifically targeted to confirm this important role of these genes in tumor development and growth and thereby demonstrate the utility of ROS-inducing anticancer agents such as CF3DODA-Me and CDDO-Me for treating this disease. This evidence concerns the gene TFF2 and familial pancreatic carcinoma.